Overview

Antistax® in Patients With Chronic Venous Insufficiency

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Quercetin